Group 1 - The core viewpoint of the news is that Haofan Bio has seen a significant increase in its stock price, rising by 5.33% to 57.15 CNY per share, with a total market capitalization of 6.172 billion CNY as of September 15 [1] - Haofan Bio, established on December 2, 2003, and listed on July 12, 2023, specializes in the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks [1] - The revenue composition of Haofan Bio's main business includes peptide synthesis reagents at 81.89%, general molecular building blocks at 10.99%, protein reagents at 6.11%, and other products at 1.01% [1] Group 2 - Among the top circulating shareholders of Haofan Bio, a fund under Huatai PineBridge has entered the top ten, with the Huatai Medical and Health Mixed Fund (470006) holding 602,500 shares, representing 1.5% of the circulating shares [2] - The Huatai Medical and Health Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.358 billion CNY, achieving a year-to-date return of 38.91% and a one-year return of 46.74% [2] - The fund manager of Huatai Medical and Health Mixed Fund is Zheng Lei, who has a tenure of 10 years and 276 days, with the fund's total asset scale at 7.072 billion CNY [3]
昊帆生物股价涨5.33%，汇添富基金旗下1只基金位居十大流通股东，持有60.25万股浮盈赚取174.11万元